Avanos Medical (AVNS) Liabilities and Shareholders Equity (2013 - 2026)

Avanos Medical has disclosed Liabilities and Shareholders Equity across 14 years of filings, most recently posting $1.1 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.1 billion, down 5.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 billion (down 24.13% YoY), and the FY2025 annual result was $1.1 billion, down 6.97% from the prior year.
• Liabilities and Shareholders Equity came in at $1.1 billion for Q1 2026 at Avanos Medical, down from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.8 billion in Q4 2022 to a low of $1.0 billion in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $1.7 billion (2024), against an average of $1.5 billion.
• Across the five-year window, Liabilities and Shareholders Equity increased 11.43% in 2022 and plunged 37.33% in 2025, its largest moves.
• Avanos Medical's Liabilities and Shareholders Equity stood at $1.8 billion in 2022, then dropped by 5.29% to $1.7 billion in 2023, then slumped by 31.8% to $1.2 billion in 2024, then retreated by 6.97% to $1.1 billion in 2025, then dropped by 2.2% to $1.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.